Tobacco Use, Knowledge of Harms, and Treatment Support Among Patients With Non‐Tobacco‐Related Cancers: A Multi‐Center Survey Study Authors: Raul Gregg‐Garcia, Vidya Dandu, Laura B Vater, Karen Suchanek Hudmon, Deborah Buckles, Nasser Hanna Published: 2026 ABSTRACT ABSTRACTPurposeTobacco smoking adversely affects cancer outcomes; yet tobacco treatment for patients with non‐tobacco‐related cancers (non‐TRCs) remains understudied. This study evaluated smoking behaviors, harm perceptions, and cessation support in this population.MethodsWe conducted a cross‐sectional survey of 124 adults who reported smoking within the past 30 days and were diagnosed with non‐TRCs at two medical centers between 2018 and 2022. Data collected included demographics, smoking behaviors, harm perceptions, quit attempts, and receipt of cessation support from oncology providers.ResultsMost participants (88%) recognized that continued smoking may shorten life expectancy; however, fewer recognized its impact on cancer recurrence (44%), treatment efficacy (46%), and treatment‐related side effects (46%). Although 81% reported prior quit attempts, only 33% received prescription medication and 22% received counseling. Follow‐up support from oncology teams was reported by 42% of participants.ConclusionPatients with non‐TRCs demonstrate substantial gaps in awareness of the cancer‐specific harms of continued smoking and report inconsistent receipt of evidence‐based cessation support. Targeted education and systematic integration of tobacco treatment into oncology care are needed to improve outcomes in this population.Keywords: cancer outcomes, oncology care, patient perceptions, smoking cessation, tobacco treatment support, tobacco use Introduction Tobacco smoking remains the leading preventable cause of morbidity and mortality in the United States and is responsible for approximately 20% of all cancers and 30% of cancer‐related deaths, with estimates reaching up to 40% of cancer deaths in some regions [1, 2, 3]. Strong causal relationships exist between tobacco use and several malignancies, commonly referred to as tobacco‐related cancers (TRCs), including lung, kidney, and bladder cancers [3, 4]. In contrast, other cancers, including breast, colorectal, and prostate cancers, are traditionally considered non‐tobacco‐related cancers (non‐TRCs), although the relationship between smoking and these malignancies is more complex. For example, while current evidence does not support a causal association between smoking and prostate cancer incidence, smoking has been associated with more aggressive disease, higher risk of progression, and increased mortality among affected individuals [5, 6]. Regardless of cancer type, continued smoking after a cancer diagnosis is associated with worse clinical outcomes, including reduced efficacy and tolerance of treatments such as chemotherapy and radiotherapy, increased treatment‐related toxicity, higher likelihood of dose reductions and postoperative complications, poorer quality of life, and increased risk of second primary malignancies [7, 8, 9, 10, 11, 12, 13, 14]. Smoking during cancer treatment is an independent adverse prognostic factor, whereas cessation has been associated with outcomes comparable to those of never‐smokers, making smoking status one of the strongest predictors of overall survival [14]. Most patients with cancer acknowledge that continued smoking negatively affects quality of life and survival [15]; however, important gaps in awareness persist, particularly among current smokers. Published data have shown that individuals who continue to smoke after a cancer diagnosis are less likely to recognize the adverse effects of smoking on treatment outcomes than never‐smokers, and greater awareness is associated with a higher likelihood of cessation [16]. The period surrounding cancer diagnosis represents a “teachable moment” for clinicians to encourage patients to quit smoking. Many patients attempt to quit after diagnosis; however, despite the availability of effective, evidence‐based treatments, including counseling and FDA‐approved medications, most quit attempts occur without formal support, and many ultimately fail [17, 18, 19, 20]. Tobacco use screening in oncology settings has improved substantially in recent years, with approximately 96% of patients now routinely screened at NCI‐designated centers. However, among those identified as current smokers, the reach of evidence‐based cessation treatment remains low, with a median of only about 15% receiving treatment and modest abstinence rates at follow‐up (median 6‐month point prevalence abstinence approximately 18%) [21]. Although most cancer centers now maintain tobacco treatment programs, persistent gaps in treatment delivery, institutional support, and patient‐facing educational resources continue to limit the effectiveness of tobacco cessation efforts in oncology care [22, 23, 24]. These gaps may be particularly pronounced among patients with cancers not traditionally associated with tobacco use (non‐TRCs), for whom both patients and clinicians may underestimate the relevance of smoking to cancer outcomes. As a result, these patients may have lower awareness of the risks of continued smoking and may be less likely to receive comprehensive cessation support. While tobacco cessation has been extensively studied in patients with TRCs, less is known about smoking behaviors, harm perceptions, and receipt of cessation support among patients with non‐TRCs, representing a critical and understudied gap in oncology care. In this study, we aimed to characterize (1) perceptions of the risks of continued smoking and (2) receipt of tobacco cessation support among adults with non‐TRCs who actively smoke. Methods Patients who were seen for non‐TRCs at the outpatient oncology clinics of Indiana University Simon Comprehensive Cancer Center (an NCI‐designated cancer center) or Eskenazi Health Hospital (an urban safety‐net medical center) in Indianapolis, Indiana, between July 2018 and April 2022, and actively smoked cigarettes were identified and recruited to complete a brief research survey. Eligibility criteria included age ≥ 18 years at the time of consent, active tobacco smoking within the previous 30 days, diagnosis of a non‐TRC at any stage, and ability to read and write in English. Exclusion criteria included the inability to provide written informed consent and the inability to complete the survey for any reason. Initial identification of potential participants was performed by chart review during routine scheduled oncology clinic appointments by an authorized research team member working with clinic staff (i.e., medical assistants and registered nurses) who routinely perform screening for tobacco use. The participants who met eligibility criteria were approached at the end of their office visit to explain the study and obtain informed consent; patients who agreed to participate were enrolled and signed a paper‐based consent form. The number of eligible patients who were approached and did not choose to participate was not recorded systematically. Participants completed an anonymous one‐page paper‐based survey (Appendix Appendix S1). Sociodemographic items regarding sex, age, race, ethnicity, level of education, and perceived comfort with household income were collected. Types of non‐TRC (breast, colorectal, prostate, testicular, sarcoma, melanoma, esophageal adenocarcinoma, or lymphoma) were assessed along with tobacco‐related items. Perceptions regarding the harms of continued smoking after cancer diagnosis were assessed with five items: increasing side effects from cancer treatments, making my cancer treatment not work as well, making my cancer more likely to come back, shortening my life, and making me more likely to get a different type of cancer. These items were each rated on a 5‐point scale (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree). Prior quit attempts were assessed, including the number of attempts, the ability to quit for more than a month or more than 6 months, and whether tobacco treatment medications, counseling, or the tobacco quitline were used. Additionally, participants were asked, whether they had heard of the free National Tobacco Quitline (1‐800‐QUIT‐NOW) and whether their cancer doctor (or a member of their staff) ever (a) advised them to quit smoking, (b) advised them to call the Tobacco Quitline, (c) prescribed or recommended a medication to help with quitting smoking, or (d) conducted follow‐up about quitting, either by phone or in person. The harm perception items were developed by the study team based on domains consistently identified in prior literature as key consequences of continued smoking in cancer patients, including treatment efficacy, toxicity, recurrence risk, and survival. Although not derived from a previously validated scale, these items were designed to reflect clinically relevant constructs used in prior survey‐based studies of cancer patient perceptions. Standard descriptive statistical analyses were computed to characterize the patient population. Given the exploratory nature of this study and the size of our sample, analyses were limited to descriptive statistics, and no inferential statistical testing was performed. For descriptive interpretation in the text, responses of “agree” and “strongly agree” were combined, as were “disagree” and “strongly disagree”; however, full response distributions are presented in Table 2. TABLE 2Participants' perceived harms of continued smoking after cancer diagnosis.Survey itemStrongly disagreeDisagreeNeutralAgreeStrongly agreeContinued smoking may shorten my life.2 (1.6%)3 (2.4%)10 (8.1%)63 (50.8%)46 (37.1%)Continued smoking may make me more likely to get a different type of cancer.2 (1.6%)4 (3.2%)21 (16.9%)58 (46.8%)39 (31.5%)Continued smoking may make my cancer more likely to come back.5 (4.1%)21 (17.1%)43 (35.0%)32 (26.0%)22 (17.9%)Continued smoking may make my cancer treatment to not work as well.6 (4.8%)22 (17.7%)39 (31.5%)42 (33.9%)15 (12.1%)Continued smoking may cause me to have more side effects from cancer treatment.7 (5.7%)22 (17.7%)38 (30.6%)41 (33.1%)16 (12.9%) Participants' perceived harms of continued smoking after cancer diagnosis. The study was approved by the Institutional Research and Ethics Board at Indiana University Simon Comprehensive Cancer Center and Eskenazi Health Hospital. Results Sociodemographics Of the 124 participants who completed the research survey, 79 (64%) were patients at the Indiana University Simon Comprehensive Cancer Center, and 45 (36%) were patients at Eskenazi Health Hospital. Most (n = 79; 63%) participants identified as female, 88 (71%) identified as White, 63 (51%) had an undergraduate or higher educational degree, and 43 (34%) described their household income as “comfortable.” The median age was 57.5 years (IQR = 51–67). Compared with US population estimates (sex female ~51%, White race ~59%, Hispanic ethnicity ~19%, and college or higher level of education ~37%) [25], the study sample included a higher proportion of female, non‐Hispanic White, and more highly educated participants (Table 1). TABLE 1Sociodemographics, type of diagnosed malignancy, smoking behaviors, and cessation attempts and support in tobacco smokers with non‐TRCs (n = 124).Variable n (%) or median (IQR)GenderFemale79 (63%)AgeAge, median (IQR)57.5 (51–67)Race/ethnicityWhite88 (71%)Black32 (26%)Hispanic2 (2%)Asian1 (< 1%)Highest degree or level of school completedGraduate4 (3%)College/undergraduate59 (48%)Tech/trade school3 (2%)High school53 (43%)Type of cancerBreast cancer62 (50%)Colorectal cancer30 (24%)Prostate cancer24 (19%)Other a 10 (8%)Packs of cigarettes smoked per day> 1 pack16 (13%)1 pack46 (37%)0.5–< 1 pack8 (6%)< 0.5 pack21 (17%)Did not answer1 (< 1%)Smoking cessationHave tried to quit smoking for good101 (81%)Quit smoking for < 1 month2 (2%)Quit smoking for 1 to 6‐month63 (63%)Quit smoking for > 6 months36 (36%)Number of smoking cessation attempts, median (IQR)4 (2–6)Methods/resources used for quit smokingNicotine replacement therapy, n (%)74 (74%)Prescription medications b , n (%)33 (33%)Counseling/behavioral therapy, n (%)22 (22%)Tobacco quitline, n (%)5 (5%)Other, n (%)15 (15%)None, n (%)19 (19%)Cessation support from oncologistHave been advised to quit smoking, n (%)110 (89%)Have been advised to call the quitline, n (%)41 (33%)Have been prescribed or recommended to use a medication to help quitting, n (%)52 (42%)Have been followed up about their smoking cessation efforts, n (%)52 (42%) a Testicular cancer, sarcoma, melanoma, esophageal adenocarcinoma, thymoma, lymphoma. b Vareniciline or bupropion. Sociodemographics, type of diagnosed malignancy, smoking behaviors, and cessation attempts and support in tobacco smokers with non‐TRCs (n = 124). Testicular cancer, sarcoma, melanoma, esophageal adenocarcinoma, thymoma, lymphoma. Vareniciline or bupropion. Type of Cancer The most common type of diagnosed cancer was breast (n = 62; 50%), followed by colorectal (n = 30; 24%), prostate (n = 24; 19%), melanoma (n = 4; 3%), esophageal adenocarcinoma (n = 2; 1.5%), sarcoma (n = 2; 1.5%), testicular (n = 1; < 1%), and lymphoma (n = 1; < 1%). Tobacco Use Behaviors All participants reported smoking in the past 30 days. The number of cigarette packs that participants reported smoking on an average day was more than one pack in 16 (13%), one pack in 46 (37%), between half a pack and one pack in 8 (6%), half a pack in 32 (25%), and less than half a pack in 21 (17%). (Table 1). Smoking Cessation Most participants (n = 101; 81%) reported that they had tried to stop smoking for good at some point; of these, 10 (10%) had tried to quit once, 19 (19%) had tried twice, 21 (21%) had tried three times, 14 (14%) had tried four times, 19 (19%) had tried between 5 and 9 times, and 18 (18%) had tried ten or more times. Sixty‐three participants (63%) were able to quit smoking for more than one month, and 36 (36%) had quit for more than six months prior to relapsing. When asked about the methods and resources used when attempting to quit, 74 (74%) used nicotine replacement therapy (patches or gum), 33 (33%) used a prescription medication (e.g., varenicline or bupropion), 22 (22%) received counseling or cognitive behavioral therapy, 5 (5%) contacted the tobacco quitline, and 15 (15%) used other non‐listed methods (e.g., vaping, hypnosis, aversion therapy, candy, cold turkey, praying). Nearly half of participants (n = 47; 47%) reported using more than one method, and 19 (19%) reported not using any resource or method to aid their cessation attempts. Overall, most participants (n = 110; 89%) answered “yes” when asked whether their oncologist had ever advised them to quit smoking. One‐third (n = 41) had been advised to call the tobacco quitline, 52 (42%) had been prescribed or recommended medication to help them quit, and 52 (42%) indicated that their oncologist or oncology team followed up about their quitting efforts. Perceptions of Continued Smoking After Cancer Diagnosis Regarding participants' perception of the effects of continued tobacco use after being diagnosed with cancer, when combining “agree” and “strongly agree” responses, 88% of participants endorsed that continued smoking may shorten their life, and 78% recognized that continued smoking increases the risk of developing a different type of cancer. In contrast, fewer participants recognized effects on cancer recurrence (44%), treatment efficacy (46%), and treatment‐related side effects (46%) (Table 2). Discussion This study characterizes smoking‐related perceptions and receipt of cessation support among patients with non‐TRCs who continue to smoke. Although most participants recognized that continued smoking adversely affects overall health and survival, fewer than half were aware of its impact on cancer‐specific outcomes, including treatment efficacy, recurrence risk, and treatment‐related toxicity. These findings suggest a gap in awareness of the direct effects of smoking on cancer treatment and prognosis that may contribute to suboptimal cessation outcomes. Patients with non‐TRCs may be particularly vulnerable to smoking‐related knowledge gaps, as their cancers are not widely perceived as being caused by smoking. This may lead both patients and clinicians to underestimate the importance of cessation, contributing to lower awareness of treatment‐related risks and fewer cessation interventions. Our findings are consistent with prior studies demonstrating lower awareness of smoking‐related harms among current smokers and among patients with cancers not traditionally linked to tobacco use [26]. Despite high rates of reported clinician advice to quit smoking, fewer participants reported receiving evidence‐based cessation support, including pharmacotherapy, counseling, or follow‐up. Published evidence similarly suggests that oncologists infrequently deliver comprehensive tobacco treatment or provide longitudinal follow‐up, with barriers including limited time, inadequate documentation of smoking status, lack of specialized training, and insufficient insurance coverage [27, 28, 29, 30]. Addressing these barriers is critical given the well‐established negative impact of continued smoking on cancer outcomes. Current clinical guidelines from the National Comprehensive Cancer Network, American Society of Clinical Oncology, and American Association of Cancer Research recommend that tobacco treatment be integrated into routine cancer care for all patients, including systematic screening, referral to behavioral counseling, and use of FDA‐approved pharmacotherapy throughout the course of treatment [20, 28]. National initiatives such as the NCI Cancer Center Cessation Initiative (C3I) have improved screening and infrastructure for tobacco treatment delivery [31]; however, our findings suggest that meaningful engagement with treatment remains limited in practice. Most participants reported multiple prior quit attempts, often without the use of evidence‐based treatments. Consistent with prior literature, relatively few participants reported using counseling or combined pharmacotherapy approaches, which are known to improve cessation rates [17, 18, 19, 21, 32, 33, 34]. These findings underscore the need for systematic integration of tobacco treatment into routine oncology care, including proactive referral to cessation services such as quitlines, community‐based programs, or in‐house tobacco treatment services; use of FDA‐approved medications; and ongoing follow‐up to support sustained abstinence. Evidence comparing tobacco treatment outcomes between patients with tobacco‐related cancers (TRCs) and non‐TRCs remains mixed. Some studies suggest higher cessation rates among patients with TRCs at diagnosis and during treatment [35], whereas others report higher smoking prevalence and lower cessation rates among TRC survivors [18]. Regardless of these differences, the overall evidence consistently supports the importance of providing effective cessation support to all patients with cancer. This study has several strengths and limitations. Regarding strengths, participants were recruited at both an NCI‐designated comprehensive cancer center and an urban safety‐net hospital, increasing the generalizability of the findings to different healthcare settings; also, our study used routine oncology visits to identify participants, reflecting real‐world clinical practices and enhancing the applicability of the results. This study highlights gaps in smoking cessation counseling and support, reinforcing the need for oncologists to integrate evidence‐based tobacco treatment into routine cancer care. On the other hand, as a small convenience sample of 124 participants from two centers, the findings are subject to limited generalizability and potential selection bias. The sample was not demographically representative, with a higher proportion of female participants, non‐Hispanic White individuals, and participants with higher educational attainment compared to national population estimates. Additionally, breast and colorectal cancers were overrepresented in this sample, which may further limit applicability to other cancer types. These factors may influence smoking behaviors, perceptions, and engagement with cessation support and should be considered when interpreting the results. In addition, the number of eligible patients approached and those who declined participation was not systematically recorded, precluding calculation of a response rate and introducing the possibility of further selection bias. Harm perception measures were not derived from a validated instrument, although they were designed to reflect clinically relevant domains identified in prior literature. All data were self‐reported and subject to recall and social desirability bias, and the cross‐sectional design limits the ability to assess temporal relationships or causality. Conclusions In conclusion, patients with non‐TRCs who continue to smoke demonstrate limited awareness of the cancer‐specific risks of continued smoking and report gaps in receipt of evidence‐based cessation support. Targeted education and systematic integration of tobacco treatment into oncology care, particularly for patients with cancers not traditionally associated with tobacco use, may help address these gaps and improve treatment outcomes. Future studies using larger, more representative samples are needed to better characterize these gaps and inform targeted interventions. Author Contributions Raul Gregg‐Garcia: data curation (equal), formal analysis (equal), writing – original draft (lead), writing – review and editing (equal). Vidya Dandu: data curation (equal), formal analysis (equal), writing – original draft (supporting), writing – review and editing (equal). Laura B. Vater: conceptualization (equal), formal analysis (equal), methodology (equal), project administration (equal), supervision (equal), writing – original draft (supporting), writing – review and editing (equal). Karen Suchanek Hudmon: data curation (equal), formal analysis (equal), methodology (equal), resources (equal), supervision (equal), writing – review and editing (equal). Deborah Buckles: data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), writing – review and editing (equal). Nasser Hanna: conceptualization (equal), data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), visualization (equal), writing – review and editing (equal). Ethics Statement This study was approved by the Indiana University Melvin and Bren Simon Comprehensive Cancer Center Institutional Review Board (protocol no. IUSCC‐0659). Consent Written informed consent was obtained from all the participants. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Appendix S1: PatientSurvey_TobaccoUseInCanc. Acknowledgments The authors have nothing to report. Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. References Associated Data Supplementary Materials Appendix S1: PatientSurvey_TobaccoUseInCanc. Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.